Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study (Q42625496)

4 November 2017

title

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study (English)

1 reference

4 November 2017

0 references

Rogers SL

1

1 reference

4 November 2017

Doody RS

series ordinal

2

1 reference

4 November 2017

Pratt RD

series ordinal

3

1 reference

4 November 2017

Ieni JR

series ordinal

4

1 reference

4 November 2017

language of work or name

English

0 references

publication date

1 May 2000

1 reference

European Neuropsychopharmacology

4 November 2017

published in

1 reference

4 November 2017

volume

10

1 reference

4 November 2017

issue

3

1 reference

4 November 2017

page(s)

195-203

1 reference

Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention.

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900067-5

7 January 2021

Cognitive decline in Alzheimer's disease: elaborating on the nature of the longitudinal factor structure of the Mini-Mental State Examination.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900067-5

7 January 2021

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900067-5

7 January 2021

Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900067-5

7 January 2021

Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900067-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900067-5

1 reference

7 January 2021

A new clinical scale for the staging of dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900067-5

7 January 2021

The incidence of dementia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900067-5

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900067-5

7 January 2021

The Clinical Dementia Rating (CDR): current version and scoring rules

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900067-5

7 January 2021

The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900067-5

7 January 2021

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900067-5

7 January 2021

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900067-5

7 January 2021

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900067-5

7 January 2021

A new rating scale for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900067-5

7 January 2021

Longitudinal evaluation of dementia of the Alzheimer type: a comparison of 3 standardized mental status examinations

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900067-5

7 January 2021

A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900067-5

7 January 2021

A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900067-5

7 January 2021

10.1016/S0924-977X(00)00067-5

Identifiers

DOI

1 reference

release_vckhg6rdq5arbp5dkvauxu77zy

4 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vckhg6rdq5arbp5dkvauxu77zy

24 November 2022

mapped directly with Wikidata item

1 reference